Why the study?
Does telmisartan, ramipril, or their combination reduce left ventricular hypertrophy in patients at high vascular risk?
Does telmisartan, ramipril, or their combination reduce left ventricular hypertrophy in patients at high vascular risk?
Telmisartan effectively reduces new-onset left ventricular hypertrophy in high-risk vascular patients, but combining it with ramipril offers no additional benefit over ramipril alone.
Answers are grounded in this paper and cite their sources.
Telmisartan may be considered for LVH prevention in high-risk patients; confirms no added benefit from dual blockade with ramipril.
In patients at high vascular risk, telmisartan is more effective than placebo in reducing LVH. New-onset LVH is reduced by 37%. The effect of combination of the 2 drugs on LVH is similar to that of ramipril alone.
No takes yet. Share an insight, caveat, or question.
Verdecchia et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: